Medicare Part D drug plans are expected to come with higher premiums and out-of-pocket deductibles, and some plans may pull ...

Treatments for achondroplasia, acute myeloid leukemia, familial chylomicronemia syndrome, immunoglobulin A nephropathy, and non-small cell lung cancer are under review.

The investigational agent is expected to provide protection against all known strains of seasonal influenza with a single dose.

Emalex received FDA authorization for an Expanded Access Program for its investigational Tourette syndrome drug. New Drug ...

The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for leniolisib for children aged 4 to 11 years with activated phosphoinositide ...

Provider directories for Medicare Advantage and AI prior authorization in select states are among the changes for 2026.

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving ...

The FDA has granted Fast Track designation to CS-1103 for the treatment of acute methamphetamine intoxication.

The FDA has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.

October is a critical month for those on Medicare. With the start of the Annual Open Enrollment Period on October 15th,those on Medicare have until Dec. 7 to join, switch, or drop a Medicare Advantage ...